Keep us posted. In the last email reply I saw from them they said, "come to India and get a cure". You might also want to ask for an exact location in India. Last time I researched no one knew where in India to get treatment at.

Caroverine is not available in the US or Canada for any purpose, as it has not been approved by the FDA. It is currently available only in Austria, Switzerland and Japan, and hopefully this year it will also be available in India. Lincoln Pharmaceuticals, an Ahmedabad based pharma company, will be marketing the drug in the country in collaboration with Phafag AG, a Swiss company based in Liechtenstein. Rajani G Patel, Joint Managing Director, Lincoln Pharma, informs, "We market various drugs for the ENT segment and while discussing with several doctors we discovered that a condition called tinnitus needed drugs for treatment in the country because there are none in the market for that purpose. Presently, there are two or three good anti-histamines but they do not have great results. As we are also into formulation development, we were suggested that we bring this drug to the market. Then we found out that a Swiss company called Phafag AG, based in Liechtenstein, is already working on clinical trials for this drug in India and we approached them. The company visited our plant, understood our marketing strength and soon after we signed an agreement to market their product."
Phafag AG claims that according to certain physiological and morphological assessments in a study done by them, a low-dose and long-term caroverine treatment might protect against 'impulse noise-induced hearing loss'. In the study, caroverine was delivered subcutaneously using an osmotic pump. As per the company, this kind of delivery has the advantage of avoiding systemic side effects. Many researchers, in their search for an effective treatment are also looking for a proper mode of drug delivery that will cause the least side effects.
Patel says, "We have already got the permission to import the raw material and to formulate and market caroverine in India is under consideration of the Drug Controller General of India (DCGI). We are waiting for that to happen within a month and then we can start the production in our factory." According to him, the product needs to be properly priced to encourage acceptance by the patient population, because apart from the injection's cost, the patient will have to pay the doctor's fee as well as the infusion is to be given under a doctor's supervision. "The cost per injectable infusion in Europe was Rs 2,000. So, after consulting doctors we realised that in order to conduct the trials and make the medicine accessible and affordable the price should be Rs 500-600 per infusion. This way, the whole treatment for a patient should come within Rs 2000," he says.
Although, this is the first step towards bringing patients affected by tinnitus closer to better treatments, this seems to be the only step as no other pharma company has come forward to invest in the R&D or even in distributing the drug to the needy population. Patel believes that one has to have a positive outlook towards this situation. "It goes one step at a time. Once we come out with the product, its success rate will be there for all to see along with its cost effectiveness, and patients will be comfortable with its use then the demand will rise. Since only Phafag AG has the rights to manufacture caroverine, once the drug is launched, we can approach bigger companies for co-manufacturing," he says.
The success rate of the drug is said to be 60-70 percent. The drug is to be given intravenously (IV), which gives a much better result; through eardrops and orally through capsules. Initially, a patient will be given the drug through IV for four to six hours, after which the patient has to take oral medication for five to six days to complete the treatment. Caroverine is already prevalent in the European market as an approved drug and has been marketed for 10 years already. Lincoln Pharma initially tried to import the consignments to India but the costs were too high to sustain, hence it was not financially viable.
What the future holds
Swaroop says that the problem is that even today we are not in a position to understand the actual etio-pathogenesis and the pharmacodynamics of the disease and that the success rate of all treatments is not even 30 percent. So no pharmaceutical company is willing to spend that much money on R&D for tinnitus. "I am sure people must be working, but it is a totally disappointing situation and every man is using his own personal judgments in treating patients. Tinnitus is a very debilitating problem. Patients face so many problems that they are usually on the verge of suicide, as a result, they have been referred to psychiatrists," he says. He continues, "A lot of companies are doing clinical trials but so far nothing has come out. The medications given for tinnitus have a lot of severe side effects because patients have to use these drugs for a very long time. This has become one of the major limiting factors in succeeding to treat tinnitus."
But, Swaroop feels very hopeful. "People are aware of the situation that with modernisation, the incidence of tinnitus is rising. Patients are coming to us as early as possible. I do not see any reason why there will not be a breakthrough. But right now, the most basic thing to do is find the focus of origination of the disease. Once that is achieved, it is just a question of time," he concludes.
aashruti.kak@expressindia.com

thanks for sharing

I waiting to hear from myn doctor, on what he thinks about this drug.

We are getting good response from Caroverine Injection in India.

Almost more than 1000 patient has been given Caroverine Injection and 800 patient recover from the tinnitus ( Cochlear Synaptic tinnitus)

It is really great news for us.

Visit website for further information www.tinnex.in

If you have any query feel free to write to me at amit@lincolnpharma.com

Regards

Amit Dwivedi 24 Mar 2011 06:12
Hi Amit


CAS number 23465-76-1

Caroverine (Spasmium, Spadon) is a drug used as a spasmolytic and otoneuroprotective (inner ear protective) agent in some countries.[1] It acts as an N-type calcium channel blocker, competitive AMPA receptor antagonist, and non-competitive NMDA receptor antagonist.[1] It also has potent antioxidant effects.[1][2]
[edit] References
^ a b c Udilova N, Kozlov AV, Bieberschulte W, Frei K, Ehrenberger K, Nohl H (January 2003). "The antioxidant activity of caroverine". Biochemical Pharmacology 65 (1): 5965. doi:10.1016/S0006-2952(02)01452-1. PMID 12473379.
^ Nohl H, Bieberschulte W, Dietrich B, Udilova N, Kozlov AV (2003). "Caroverine, a multifunctional drug with antioxidant functions". BioFactors 19 (12): 7985. doi:10.1002/biof.5520190110. PMID 14757980.

"800 patient recover from the tinnitus"

do they claim the result is going to be permanent? this sounds almost surreal, i wish and pray it's true

So far, everybody tells you the same thing.

But nobody ever produces the finished product.

Where are all the people he is talking about.

Why is it, that they are not talking about their personal experiences on the internet.

It is very frustrated.

That seems pretty common for most companies that advertise cures. Thousands of people are helped but youll never find a single one.

Well I can tell you one thing. If they don't start producing live patients, to give testimonials, then they are just shooting themselves in the foot